市场调查报告书
商品编码
1519789
2024-2032 年无针给药技术市场(按产品、应用、最终用户和地区划分)Needle-free Drug Delivery Technology Market by Product, Application, End User, and Region 2024-2032 |
IMARC Group年全球无针给药技术市场规模达44亿美元。慢性病盛行率不断上升、老年人口不断增加以及雷射无针注射技术(NFIT)的最新发展是推动市场发展的一些关键因素。
无针给药技术是指不使用传统针头给药给病人的方法。它包括微喷嘴喷射注射器、透皮贴片、吸入器、一次性药筒注射器、鼻喷剂和超音波。它们广泛用于疫苗接种、胰岛素输送、疼痛管理、荷尔蒙治疗以及过敏、癌症、呼吸系统疾病和其他慢性疾病的治疗。与传统的针头给药系统相比,无针给药技术可以减轻疼痛,最大限度地减少不适和焦虑,提高便利性,提高患者依从性,允许剂量定制,并防止受伤和感染的风险。它还提供更快的药物输送,有助于增强药物吸收、最大限度地减少併发症并提高治疗效果。无针给药技术也是环保的,因为它最大限度地减少了危险废物的产生,减少了製造排放,并消除了产品处置的需要。
糖尿病、癌症、克隆氏症、多发性硬化症、关节炎、骨质疏鬆症和心血管疾病(CVD)等慢性病盛行率不断上升,是推动市场成长的主要因素之一。无针给药技术广泛用于向慢性病患者输送胰岛素和药物,而不会产生疼痛和不适,从而改善治疗效果,降低感染风险,并提高患者的生活品质。此外,广泛采用的技术来提高药物依从性、增加药物吸收、提高治疗效果并最大限度地减少与针头相关的併发症,这是另一个生长诱导因素。此外,最近开发的雷射无针注射技术(NFIT)正在对市场成长产生积极影响,该技术利用雷射系统将药物以高精度喷射到皮肤中。此外,增加兽医护理中的技术利用,以人道和无压力的方式给动物注射疫苗、药物和麻醉,有利于市场成长。除此之外,政府为促进采用无针给药系统和支持先进技术的发展而采取的各种措施的实施,正在为市场成长创造积极的前景。其他因素包括由于传染病日益流行而对疫苗的需求不断增加、老年人口不断增加、医疗保健行业的显着增长、广泛的研发 (R&D) 活动以及消费者对无针给药益处的认识不断增强技术,预计将推动市场成长。
The global needle-free drug delivery technology market size reached US$ 4.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.56% during 2024-2032. The escalating prevalence of chronic diseases, the increasing geriatric population, and the recent development of laser-powered needle-free injection technology (NFIT) represent some of the key factors driving the market.
Needle-free drug delivery technology refers to a method of administering medications to patients without using traditional needles. It includes micronozzle jet injectors, transdermal patches, inhalers, disposable cartridge injectors, nasal sprays, and ultrasound waves. They are widely used for vaccinations, insulin delivery, pain management, hormone therapy, and treating allergies, cancer, respiratory conditions, and other chronic diseases. As compared to traditional needle-based delivery systems, needle-free drug delivery technology reduces pain, minimizes discomfort and anxiety, enhances convenience, improves patient compliance, allows dosage customization, and prevents the risk of injuries and infections. It also offers faster medication delivery and aids in enhancing drug absorption, minimizing complications, and increasing treatment effectiveness. Needle-free drug delivery technology is also eco-friendly as it minimizes hazardous waste generation, reduces manufacturing emissions, and eliminates the need for product disposal.
The escalating prevalence of chronic diseases, such as diabetes, cancer, Crohn's disease, multiple sclerosis, arthritis, osteoporosis, and cardiovascular diseases (CVDs), is one of the primary factors driving the market growth. Needle-free drug delivery technology is widely used to deliver insulin and medications to chronic disease patients without pain and discomfort, which improves treatment outcomes, reduces the risk of infections, and enhances patients' quality of life. Furthermore, the widespread technology adoption to improve medication adherence, increase drug absorption, enhance treatment effectiveness, and minimize complications associated with needles is acting as another growth-inducing factor. Additionally, the recent development of a laser-powered needle-free injection technology (NFIT), which utilizes a laser-based system to blast microscopic jets of drugs into the skin with high precision, is positively influencing the market growth. Moreover, increasing technology utilization in veterinary care to administer vaccines, medications, and anesthesia to animals in a humane and stress-free manner is favoring the market growth. Apart from this, the implementation of various government initiatives to promote the adoption of needle-free drug delivery systems and support the development of advanced technologies are creating a positive outlook for the market growth. Other factors, including rising demand for vaccines due to the increasing prevalence of infectious diseases, increasing geriatric population, significant growth in the healthcare industry, extensive research and development (R&D) activities, and growing consumer awareness regarding the benefits of needle-free drug delivery technology, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global needle-free drug delivery technology market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, application, and end user.
Inhaler
Jet Injector
Novel Needles
Transdermal Patch
Others
The report has provided a detailed breakup and analysis of the needle-free drug delivery technology market based on the product. This includes inhaler, jet injector, novel needles, transdermal patch, and others.
Vaccine Delivery
Pain Management
Insulin Delivery
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the application has also been provided in the report. This includes vaccine delivery, pain management, insulin delivery, and others.
Hospitals and Clinics
Homecare Settings
Research Laboratories
Academics
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the end user has also been provided in the report. This includes hospitals and clinics, homecare settings, research laboratories, academics, and others.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for needle-free drug delivery technology. Some of the factors driving the North America needle-free drug delivery technology market included the increasing prevalence of chronic diseases, the implementation of various government initiatives, and rapid technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global needle-free drug delivery technology market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.